Breaking News Instant updates and real-time market news.

SNWV

Sanuwave Health

$0.00 /

+ (+0.00%)

09:08
11/17/20
11/17
09:08
11/17/20
09:08

Sanuwave Health reports Q3 EPS (2c) vs. (1c) last year

Reports Q3 revenue $1.97M vs. $197,640 last year ."The third quarter was transformational for SANUWAVE as we added UltraMist, BIOVANCE and Interfyl to our portfolio to create a market-leading provider of advanced wound care solutions that improves clinical outcomes across the continuum of care. The combination of our two powerful wound care offerings was evidenced in our record revenue in the third quarter 2020; is expected to increase product revenue by approximately 50% in the fourth quarter; and should further accelerate our growth throughout 2021," stated CEO Kevin Richardson. "We are particularly pleased to have surpassed our integration timelines by three months and now have a cohesive team that is fully aligned and focused on achieving our goals to drive revenue and bring our suite of advanced wound care products to patients in need. Since closing the transaction in late August, we are off to a strong start and are pleased with the traction we are gaining in the market. We continue to invest in having a strong presence at key medical conferences where we support the use dermaPACE and UltraMist before an audience of leading wound care clinicians. In addition, we are now using data driven tools to pinpoint areas with the strongest addressable markets for our wound care solutions and are increasing our footprint in those geographies, where we are beginning to see the results of those initiatives. We expanded our geographic reach in Latin America with regulatory approvals for dermaPACE to treat chronic wounds in Mexico and Brazil. Overall, international growth is expected to be strong with plans for nearly ten device placements in the fourth quarter. These placements should provide long-term recurring revenue as our partners gain traction through education and promotion of the clinical benefits of our advanced wound healing products in their respective regions."

SNWV Sanuwave Health
$0.00 /

+ (+0.00%)

09/15/20 Lake Street
Sanuwave Health initiated with a Buy at Lake Street

TODAY'S FREE FLY STORIES

Recommendations
Bentley Systems price target raised to $53 from $50 at Mizuho » 06:54
03/03/21
03/03
06:54
03/03/21
06:54
BSY

Bentley Systems

/

+

Mizuho analyst Matthew…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BSY Bentley Systems
/

+

BSY Bentley Systems
/

+

01/12/21 Mizuho
Bentley Systems price target raised to $50 from $44 at Mizuho
11/16/20 RBC Capital
Bentley Systems upgraded to Outperform from Sector Perform at RBC Capital
10/19/20
Fly Intel: Top five analyst initiations
10/19/20 KeyBanc
Bentley Systems initiated with a Sector Weight at KeyBanc
BSY Bentley Systems
/

+

  • 13
    Nov
  • 23
    Sep
BSY Bentley Systems
/

+

BSY Bentley Systems
/

+

Downgrade
Adaptive Biotechnologies downgraded to Neutral from Buy at Goldman Sachs » 06:54
03/03/21
03/03
06:54
03/03/21
06:54
ADPT

Adaptive Biotechnologies

$53.11 /

-4.75 (-8.21%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ADPT Adaptive Biotechnologies
$53.11 /

-4.75 (-8.21%)

RHHBY Roche
$0.00 /

+ (+0.00%)

ADPT Adaptive Biotechnologies
$53.11 /

-4.75 (-8.21%)

01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
12/17/20 BTIG
BTIG positive on select healthcare diagnostic/tools names as '2021 Top Picks'
11/12/20 BTIG
Adaptive Biotechnologies price target raised to $63 from $60 at BTIG
11/11/20 JPMorgan
Adaptive Biotechnologies price target raised to $60 from $50 at JPMorgan
RHHBY Roche
$0.00 /

+ (+0.00%)

02/25/21 Berenberg
Roche price target lowered to CHF 320 from CHF 325 at Berenberg
02/24/21 Morgan Stanley
Roche price target lowered to CHF 345 from CHF 365 at Morgan Stanley
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/17/21 UBS
UBS downgrades Roche to Neutral on risk to 2022 estimates
ADPT Adaptive Biotechnologies
$53.11 /

-4.75 (-8.21%)

RHHBY Roche
$0.00 /

+ (+0.00%)

  • 16
    Jul
RHHBY Roche
$0.00 /

+ (+0.00%)

ADPT Adaptive Biotechnologies
$53.11 /

-4.75 (-8.21%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Upgrade
3D Systems upgraded to Hold from Sell at Loop Capital » 06:54
03/03/21
03/03
06:54
03/03/21
06:54
DDD

3D Systems

$31.14 /

-7.6 (-19.62%)

Loop Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
DDD 3D Systems
$31.14 /

-7.6 (-19.62%)

DDD 3D Systems
$31.14 /

-7.6 (-19.62%)

05:34 Today Loop Capital
3D Systems upgraded to Hold from Sell at Loop Capital
01/29/21 Craig-Hallum
3D Systems downgraded to Hold from Buy at Craig-Hallum
01/29/21 Craig-Hallum
3D Systems downgraded to Hold from Buy at Craig-Hallum
01/25/21
Fly Intel: Top five analyst downgrades
DDD 3D Systems
$31.14 /

-7.6 (-19.62%)

DDD 3D Systems
$31.14 /

-7.6 (-19.62%)

DDD 3D Systems
$31.14 /

-7.6 (-19.62%)

Hot Stocks
Boston Scientific to acquire surgical business of Lumenis for $1.07B » 06:53
03/03/21
03/03
06:53
03/03/21
06:53
BSX

Boston Scientific

$38.76 /

-0.135 (-0.35%)

Boston Scientific…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BSX Boston Scientific
$38.76 /

-0.135 (-0.35%)

BSX Boston Scientific
$38.76 /

-0.135 (-0.35%)

02/03/21 Piper Sandler
Boston Scientific price target raised to $48 from $46 at Piper Sandler
02/01/21
Fly Intel: Top five analyst initiations
02/01/21 Deutsche Bank
Boston Scientific initiated with a Hold at Deutsche Bank
01/25/21 Morgan Stanley
iRhythm price target raised to $288 from $227 at Morgan Stanley
BSX Boston Scientific
$38.76 /

-0.135 (-0.35%)

  • 22
    May
BSX Boston Scientific
$38.76 /

-0.135 (-0.35%)

BSX Boston Scientific
$38.76 /

-0.135 (-0.35%)

Upgrade
M3 Inc. upgraded to Buy from Neutral at Citi » 06:53
03/03/21
03/03
06:53
03/03/21
06:53
MTHRF

M3 Inc.

$0.00 /

+ (+0.00%)

Citi analyst Hidemaru…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MTHRF M3 Inc.
$0.00 /

+ (+0.00%)

11/18/20 Credit Suisse
M3 Inc. upgraded to Outperform from Neutral at Credit Suisse
08/19/20 Mizuho
M3 Inc. upgraded to Buy from Neutral at Mizuho
04/07/20 Morgan Stanley
M3 Inc. upgraded to Overweight from Equal Weight at Morgan Stanley
Hot Stocks
Adaptive says Genentech suspends development of shared antigen target candidate » 06:53
03/03/21
03/03
06:53
03/03/21
06:53
ADPT

Adaptive Biotechnologies

$53.11 /

-4.75 (-8.21%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

In a regulatory filing…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ADPT Adaptive Biotechnologies
$53.11 /

-4.75 (-8.21%)

RHHBY Roche
$0.00 /

+ (+0.00%)

ADPT Adaptive Biotechnologies
$53.11 /

-4.75 (-8.21%)

01/19/21 BTIG
Adaptive Biotechnologies price target raised to $74 from $66 at BTIG
12/17/20 BTIG
BTIG positive on select healthcare diagnostic/tools names as '2021 Top Picks'
11/12/20 BTIG
Adaptive Biotechnologies price target raised to $63 from $60 at BTIG
11/11/20 JPMorgan
Adaptive Biotechnologies price target raised to $60 from $50 at JPMorgan
RHHBY Roche
$0.00 /

+ (+0.00%)

02/25/21 Berenberg
Roche price target lowered to CHF 320 from CHF 325 at Berenberg
02/24/21 Morgan Stanley
Roche price target lowered to CHF 345 from CHF 365 at Morgan Stanley
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/17/21 UBS
UBS downgrades Roche to Neutral on risk to 2022 estimates
ADPT Adaptive Biotechnologies
$53.11 /

-4.75 (-8.21%)

RHHBY Roche
$0.00 /

+ (+0.00%)

  • 16
    Jul
RHHBY Roche
$0.00 /

+ (+0.00%)

ADPT Adaptive Biotechnologies
$53.11 /

-4.75 (-8.21%)

RHHBY Roche
$0.00 /

+ (+0.00%)

Initiation
Natixis resumed with a Buy at Citi » 06:51
03/03/21
03/03
06:51
03/03/21
06:51
NTXFY

Natixis

$0.00 /

+ (+0.00%)

Citi analyst Azzurra…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NTXFY Natixis
$0.00 /

+ (+0.00%)

NTXFY Natixis
$0.00 /

+ (+0.00%)

02/10/21 RBC Capital
Natixis downgraded to Sector Perform from Outperform at RBC Capital
02/10/21 Societe Generale
Natixis upgraded to Hold from Sell at Societe Generale
01/27/21 Societe Generale
Natixis downgraded to Sell from Hold at Societe Generale
01/07/21 Credit Suisse
Natixis downgraded to Underperform from Neutral at Credit Suisse
Hot Stocks
Eli Lilly, Incyte announce BRAVE-AA2 study met primary endpoint » 06:51
03/03/21
03/03
06:51
03/03/21
06:51
LLY

Eli Lilly

$204.13 /

-2.26 (-1.10%)

, INCY

Incyte

$78.57 /

-1.12 (-1.41%)

Eli Lilly (LLY) and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

03/02/21 JPMorgan
Eli Lilly risk/reward favorable into Alzheimer's data, says JPMorgan
02/18/21 H.C. Wainwright
Rigel Pharmaceuticals price target raised to $11 from $8 at H.C. Wainwright
02/18/21 Piper Sandler
Rigel share setup 'distinctly positive' after Lilly deal, says Piper Sandler
02/12/21 Cowen
Eli Lilly price target raised to $235 from $195 at Cowen
INCY Incyte
$78.57 /

-1.12 (-1.41%)

02/10/21 SVB Leerink
Incyte downgraded to Market Perform from Outperform at SVB Leerink
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/07/21 Truist
Incyte initiated with a Buy at Truist
01/04/21 Guggenheim
Incyte upgraded to Buy from Neutral at Guggenheim
LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

LLY Eli Lilly
$204.13 /

-2.26 (-1.10%)

INCY Incyte
$78.57 /

-1.12 (-1.41%)

Earnings
OneSpaWorld reports Q4 EPS (33c), consensus (21c) » 06:48
03/03/21
03/03
06:48
03/03/21
06:48
OSW

OneSpaWorld

$11.54 /

+0.16 (+1.41%)

Reports Q4 revenue $3.8M,…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OSW OneSpaWorld
$11.54 /

+0.16 (+1.41%)

OSW OneSpaWorld
$11.54 /

+0.16 (+1.41%)

01/13/21 Jefferies
OneSpaWorld downgraded to Hold at Jefferies following over 50% rally
01/13/21 Jefferies
OneSpaWorld downgraded to Hold from Buy at Jefferies
10/30/20 Stifel
CDC lifting 'no sail order' a 'clear positive' for cruise liners, says Stifel
06/09/20 Stifel
OneSpaWorld price target raised to $10 from $7 at Stifel
OSW OneSpaWorld
$11.54 /

+0.16 (+1.41%)

Downgrade
PNM Resources downgraded to Neutral from Buy at Citi » 06:48
03/03/21
03/03
06:48
03/03/21
06:48
PNM

PNM Resources

$47.66 /

-0.385 (-0.80%)

Citi analyst Ryan Levine…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
PNM PNM Resources
$47.66 /

-0.385 (-0.80%)

PNM PNM Resources
$47.66 /

-0.385 (-0.80%)

01/06/21 Wells Fargo
PNM Resources downgraded to Underweight from Equal Weight at Wells Fargo
11/18/20
Fly Intel: Top five analyst downgrades
11/18/20 Barclays
PNM Resources downgraded to Underweight from Equal Weight at Barclays
10/26/20 UBS
PNM Resources downgraded to Neutral from Buy at UBS
PNM PNM Resources
$47.66 /

-0.385 (-0.80%)

Hot Stocks
Junshi, Coherus BioSciences initiate rolling submission of BLA for toripalimab » 06:48
03/03/21
03/03
06:48
03/03/21
06:48
CHRS

Coherus Biosciences

$15.69 /

-0.38 (-2.36%)

Junshi Biosciences and…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CHRS Coherus Biosciences
$15.69 /

-0.38 (-2.36%)

CHRS Coherus Biosciences
$15.69 /

-0.38 (-2.36%)

02/25/21 Citi
Coherus Biosciences price target lowered to $27 from $30 at Citi
02/25/21 H.C. Wainwright
Coherus Biosciences price target lowered to $29 from $33 at H.C. Wainwright
11/19/20 Mizuho
Coherus Biosciences price target lowered to $30 from $35 at Mizuho
08/21/20 Mizuho
Express Scripts exclusion does not impact Coherus, says Mizuho
CHRS Coherus Biosciences
$15.69 /

-0.38 (-2.36%)

Recommendations
Cinemark price target raised to $30 from $21 at Benchmark » 06:48
03/03/21
03/03
06:48
03/03/21
06:48
CNK

Cinemark

$23.87 /

-0.06 (-0.25%)

Benchmark analyst Michael…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CNK Cinemark
$23.87 /

-0.06 (-0.25%)

CNK Cinemark
$23.87 /

-0.06 (-0.25%)

02/23/21 Wedbush
Cinemark price target raised to $28 from $15 at Wedbush
02/01/21 MKM Partners
Cinemark downgraded to Neutral from Buy at MKM Partners
02/01/21 MKM Partners
Cinemark downgraded to Neutral from Buy at MKM Partners
01/25/21 Goldman Sachs
Cinemark price target raised to $16 from $11 at Goldman Sachs
CNK Cinemark
$23.87 /

-0.06 (-0.25%)

CNK Cinemark
$23.87 /

-0.06 (-0.25%)

CNK Cinemark
$23.87 /

-0.06 (-0.25%)

CNK Cinemark
$23.87 /

-0.06 (-0.25%)

Recommendations
Clover Health price target lowered to $13 from $19 at Citi » 06:47
03/03/21
03/03
06:47
03/03/21
06:47
CLOV

Clover Health

$9.04 /

-1.35 (-12.99%)

Citi analyst Ralph…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CLOV Clover Health
$9.04 /

-1.35 (-12.99%)

CLOV Clover Health
$9.04 /

-1.35 (-12.99%)

02/02/21
Fly Intel: Top five analyst initiations
02/02/21 Citi
Clover Health initiated with a Buy at Citi
02/01/21 JPMorgan
Clover Health initiated with a Neutral at JPMorgan
CLOV Clover Health
$9.04 /

-1.35 (-12.99%)

CLOV Clover Health
$9.04 /

-1.35 (-12.99%)

CLOV Clover Health
$9.04 /

-1.35 (-12.99%)

Recommendations
Nutanix estimates raised as several drivers seen, says Susquehanna » 06:46
03/03/21
03/03
06:46
03/03/21
06:46
NTNX

Nutanix

$29.93 /

-0.795 (-2.59%)

Susquehanna analyst Mehdi…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
NTNX Nutanix
$29.93 /

-0.795 (-2.59%)

NTNX Nutanix
$29.93 /

-0.795 (-2.59%)

02/25/21 KeyBanc
Nutanix price target raised to $42 from $37 at KeyBanc
02/25/21 Wells Fargo
Nutanix price target raised to $40 from $35 at Wells Fargo
02/25/21 Needham
Nutanix price target raised to $43 from $37 at Needham
01/13/21 William Blair
VMware downgraded to Market Perform at William Blair after executive exits
NTNX Nutanix
$29.93 /

-0.795 (-2.59%)

NTNX Nutanix
$29.93 /

-0.795 (-2.59%)

NTNX Nutanix
$29.93 /

-0.795 (-2.59%)

Recommendations
Niu Technologies price target raised to $48 from $37 at Citi » 06:46
03/03/21
03/03
06:46
03/03/21
06:46
NIU

Niu Technologies

$38.28 /

-2.08 (-5.15%)

Citi analyst Beatrice Lam…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NIU Niu Technologies
$38.28 /

-2.08 (-5.15%)

NIU Niu Technologies
$38.28 /

-2.08 (-5.15%)

01/15/21 Needham
Niu Technologies price target raised to $46 from $36 at Needham
11/06/20 Citi
Niu Technologies upgraded to Buy from Neutral at Citi
10/12/20 Piper Sandler
Niu Technologies price target raised to $31 from $25 at Piper Sandler
08/17/20 Citi
Niu Technologies downgraded to Neutral from Buy at Citi
NIU Niu Technologies
$38.28 /

-2.08 (-5.15%)

General news
FX Action: Broad weakness in the Japanese currency has maintained buoyancy in USD-JPY » 06:45
03/03/21
03/03
06:45
03/03/21
06:45

FX Action: Broad weakness…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

General news
Week of 2/26 MBA Mortgage Applications to be released at 07:00  06:45
03/03/21
03/03
06:45
03/03/21
06:45
 
Recommendations
21Vianet price target raised to $47 from $33 at Citi » 06:43
03/03/21
03/03
06:43
03/03/21
06:43
VNET

21Vianet

$37.43 /

-1.305 (-3.37%)

Citi analyst Arthur Lai…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VNET 21Vianet
$37.43 /

-1.305 (-3.37%)

VNET 21Vianet
$37.43 /

-1.305 (-3.37%)

11/04/20 Daiwa
21Vianet initiated with a Buy at Daiwa
09/28/20 BofA
21Vianet initiated with a Buy at BofA
09/28/20 BofA
21Vianet initiated with a Buy at BofA
07/14/20 UBS
21Vianet initiated with a Buy at UBS
VNET 21Vianet
$37.43 /

-1.305 (-3.37%)

  • 26
    Aug
  • 05
    Mar
VNET 21Vianet
$37.43 /

-1.305 (-3.37%)

Recommendations
Mayville Engineering results suggest volume recovery continues, says Baird » 06:42
03/03/21
03/03
06:42
03/03/21
06:42
MEC

Mayville Engineering

$15.15 /

+0.44 (+2.99%)

Baird analyst Mircea…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MEC Mayville Engineering
$15.15 /

+0.44 (+2.99%)

MEC Mayville Engineering
$15.15 /

+0.44 (+2.99%)

02/04/21 Baird
Mayville Engineering price target raised to $20 from $14 at Baird
11/04/20 Citi
Mayville Engineering price target raised to $13 from $10 at Citi
08/21/20
Fly Intel: Top five analyst upgrades
08/21/20 UBS
Mayville Engineering upgraded to Buy from Neutral at UBS
MEC Mayville Engineering
$15.15 /

+0.44 (+2.99%)

Hot Stocks
Stellantis sees 2021 adjusted operating income margin of 5.5%-7.5%  06:42
03/03/21
03/03
06:42
03/03/21
06:42
STLA

Stellantis

$17.00 /

+0.13 (+0.77%)

 
ShowHide Related Items >><<
STLA Stellantis
$17.00 /

+0.13 (+0.77%)

STLA Stellantis
$17.00 /

+0.13 (+0.77%)

03/02/21 AlphaValue
Stellantis upgraded to Buy from Add at AlphaValue
02/24/21
Fly Intel: Top five analyst initiations
02/24/21 Citi
Stellantis resumed with a Buy at Citi
02/10/21 Morgan Stanley
Renault downgraded to Equal Weight from Overweight at Morgan Stanley
STLA Stellantis
$17.00 /

+0.13 (+0.77%)

STLA Stellantis
$17.00 /

+0.13 (+0.77%)

Recommendations
Citi boosts Micron target to $116, still sees $150 stock longer term » 06:42
03/03/21
03/03
06:42
03/03/21
06:42
MU

Micron

$91.02 /

-3.74 (-3.95%)

Citi analyst Christopher…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MU Micron
$91.02 /

-3.74 (-3.95%)

MU Micron
$91.02 /

-3.74 (-3.95%)

03/02/21 Evercore ISI
Micron price target raised to $135 from $105 at Evercore ISI
03/01/21 Wedbush
Micron price target raised to $100 from $88 at Wedbush
03/01/21 Barclays
Micron price target raised to $110 from $100 at Barclays
02/25/21 Mizuho
Micron price target raised to $100 from $85 at Mizuho
MU Micron
$91.02 /

-3.74 (-3.95%)

MU Micron
$91.02 /

-3.74 (-3.95%)

MU Micron
$91.02 /

-3.74 (-3.95%)

MU Micron
$91.02 /

-3.74 (-3.95%)

Hot Stocks
Stellantis: Fiat Chrysler reports 2020 adjusted net profit EUR1.86B » 06:42
03/03/21
03/03
06:42
03/03/21
06:42
STLA

Stellantis

$17.00 /

+0.13 (+0.77%)

Fiat Chrysler reported…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
STLA Stellantis
$17.00 /

+0.13 (+0.77%)

STLA Stellantis
$17.00 /

+0.13 (+0.77%)

03/02/21 AlphaValue
Stellantis upgraded to Buy from Add at AlphaValue
02/24/21
Fly Intel: Top five analyst initiations
02/24/21 Citi
Stellantis resumed with a Buy at Citi
02/10/21 Morgan Stanley
Renault downgraded to Equal Weight from Overweight at Morgan Stanley
STLA Stellantis
$17.00 /

+0.13 (+0.77%)

STLA Stellantis
$17.00 /

+0.13 (+0.77%)

Syndicate
VICI Properties files to sell 60M shares of common stock » 06:41
03/03/21
03/03
06:41
03/03/21
06:41
VICI

VICI Properties

$28.63 /

-0.3 (-1.04%)

Morgan Stanley, BofA…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VICI VICI Properties
$28.63 /

-0.3 (-1.04%)

VICI VICI Properties
$28.63 /

-0.3 (-1.04%)

02/22/21 Deutsche Bank
VICI Properties price target raised to $32 from $28 at Deutsche Bank
01/26/21 Goldman Sachs
VICI Properties price target raised to $33 from $27 at Goldman Sachs
12/17/20 JPMorgan
VICI Properties initiated with an Overweight at JPMorgan
12/16/20 Baird
VICI Properties reinstated with an Outperform at Baird
VICI VICI Properties
$28.63 /

-0.3 (-1.04%)

  • 17
    Jun
Recommendations
B&G Foods price target lowered to $29 from $32 at RBC Capital » 06:41
03/03/21
03/03
06:41
03/03/21
06:41
BGS

B&G Foods

$30.44 /

-0.36 (-1.17%)

RBC Capital analyst Nik…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
BGS B&G Foods
$30.44 /

-0.36 (-1.17%)

BGS B&G Foods
$30.44 /

-0.36 (-1.17%)

01/19/21 Stephens
B&G Foods initiated with an Equal Weight at Stephens
01/05/21 Credit Suisse
B&G Foods downgraded to Underperform from Neutral at Credit Suisse
07/28/20 Seaport Global
B&G Foods initiated with a Neutral at Seaport Global
06/12/20
Fly Intel: Top five analyst initiations
BGS B&G Foods
$30.44 /

-0.36 (-1.17%)

BGS B&G Foods
$30.44 /

-0.36 (-1.17%)

BGS B&G Foods
$30.44 /

-0.36 (-1.17%)

Recommendations
Abercrombie & Fitch price target raised to $33 from $28 at Citi » 06:40
03/03/21
03/03
06:40
03/03/21
06:40
ANF

Abercrombie & Fitch

$27.15 /

-0.39 (-1.42%)

Citi analyst Paul Lejuez…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ANF Abercrombie & Fitch
$27.15 /

-0.39 (-1.42%)

ANF Abercrombie & Fitch
$27.15 /

-0.39 (-1.42%)

06:34 Today RBC Capital
Abercrombie & Fitch price target raised to $30 from $27 at RBC Capital
02/16/21 JPMorgan
Abercrombie & Fitch price target raised to $27 from $26 at JPMorgan
01/14/21 JPMorgan
Abercrombie & Fitch price target raised to $26 from $24 at JPMorgan
12/30/20 B. Riley Securities
B. Riley checks show holiday outperformance for four retailers
ANF Abercrombie & Fitch
$27.15 /

-0.39 (-1.42%)

ANF Abercrombie & Fitch
$27.15 /

-0.39 (-1.42%)

ANF Abercrombie & Fitch
$27.15 /

-0.39 (-1.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.